Kymab Ltd.
https://www.kymab.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kymab Ltd.
Finance Watch: Frontier Raises $80m For Differentiated KRAS G12C Program
Private Company Edition: With its lead program in the clinic, Frontier’s $80m series C round will fund trials for additional programs. Also, ORI raises $260m for second fund, Earlybird closed a €173m ($187.1m) fund, Areteia’s series A grew to $425m and Sudo’s series B increased to $147m.
UK's T-Therapeutics Raises Almost $60m Despite Tough Funding Environment
CEO Allan Bradley tells Scrip that “we're at the very beginning of what I believe will be an explosion of TCR-based therapeutics” and his start-up hopes to take a leading position.
Sanofi Looks To Build On Dupixent Dominance With OX40L Drug
Sanofi is looking to build its position in immunology, with a new anti-inflammatory candidate, amlitelimab, which could potentially help patients who do not respond to its blockbuster Dupixent.
Sanofi Goes All In For Type 1 Diabetes With Provention Buy
Sanofi is taking full control of the recently approved type 1 diabetes prevention therapy Tzield by splashing out $2.9bn to acquire partner Provention.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Synthesis Technologies, Production Processes
- Transgenics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice